Could lung cancer patients get immunotherapy less often?
NCT ID NCT04032418
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immunotherapy drug pembrolizumab every 12 weeks works as well as the standard every 3 weeks in people with non-small cell lung cancer who are already benefiting from the drug. The goal is to see if fewer treatments can keep the cancer under control while reducing hospital visits and costs. About 9 participants are enrolled in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- New combo aims to stall lung Cancer's spread
- New tool may help older cancer patients avoid harsh chemo side effects
- DNA vaccine aims to train immune system against lung cancer
- Lung cancer vaccine shows promise in early prevention trial
- New radiation technique could boost immunotherapy in advanced lung cancer